with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the ...

You are responsible for reading, understanding, and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy ...

Desmopressin is approved in various forms, but these do not meet the paediatric need for precise, titratable and small doses.

Eton Pharma gets US patent covering its ET-600 product candidate’s proprietary formulation of desmopressin oral solution: Deer Park, Illinois Monday, February 10, 2025, 11:00 Hr ...

Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the ...

Eton Pharmaceuticals (ETON) announced that the United States Patent and Trademark Office has granted the company U.S. Patent No. 12,214,010, ...

Stifel analysts have maintained a Buy rating and a $28.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), focusing on the company's recent developments. Currently trading at $5.59, ...

In the Notice Letter in January 2023, Teva stated that it intended to market a generic version of Firdapse before the expiration of multiple of Catalyst’s patents listed in the FDA Orange Book.